Opinion|Videos|May 23, 2025
CROI 2025 Insights: Evolving HIV Treatment Landscape and Practice-Changing Developments
Author(s)Sharon Walmsley, CM, MD, FRCPC
A panelist discusses how HIV treatment has evolved with tremendous improvements in efficacy, tolerability, and convenience, with exciting developments at the Conference on Retroviruses and Opportunistic Infections 2025, including new long-acting therapies for treatment and prevention that could last up to 2 years.
Advertisement
Future Directions in HIV Treatment
Key Themes:
- Treatment Evolution: Continuous improvement in HIV medications regarding efficacy, tolerability, and convenience
- Long-Acting Formulations: Development of oral, subcutaneous, intramuscular, and intravenous options
- Combination Products: Future devices potentially combining HIV treatment/prevention with contraception or sexually transmitted infection prevention
- HIV Prevention: New preventive therapies potentially effective for 1 to 2 years
Notable Insights from Dr Sharon Walmsley:
- Long-acting therapies help “demedicalize” HIV by reducing medication frequency.
- New challenges in adherence emerge with transition from daily to weekly or monthly dosing schedules.
- HIV treatment advances have informed approaches to other infectious diseases, including COVID-19 and Mpox.
- Despite prevention advances, questions remain about whether to continue vaccine development efforts given limited success to date.
Advertisement
Related to this article
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS
3
GLP-1 Receptor Agonists Cut Ascites, Mortality in MASH
4
Hepatitis A Vaccine Prevents 96% of Infections Given Before Exposure
5